Eli Lilly (LLY) Cash from Investing Activities (2009 - 2026)

Eli Lilly (LLY) has reported Cash from Investing Activities for 18 consecutive years, with -$3.9 billion the latest figure, recorded in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$3.9 billion, down 16.79% year-over-year; the trailing twelve-month figure through Mar 2026 was -$11.5 billion (down 0.5% YoY), and the FY2025 annual result was -$11.0 billion, down 17.95% from the prior year.
• Cash from Investing Activities was -$3.9 billion for Q1 2026 at Eli Lilly, down from -$2.8 billion in the prior quarter.
• Over five years, Cash from Investing Activities peaked at -$459.1 million in Q2 2023 and troughed at -$4.0 billion in Q3 2024.
• Average Cash from Investing Activities over 5 years is -$2.1 billion, with a median of -$1.9 billion recorded in 2024.
• Year-over-year, Cash from Investing Activities soared 44.45% in 2023 and tumbled 378.92% in 2024.
• Over 5 years, Cash from Investing Activities stood at -$943.5 million in 2022, then sank by 209.97% to -$2.9 billion in 2023, then surged by 34.32% to -$1.9 billion in 2024, then sank by 45.87% to -$2.8 billion in 2025, then plunged by 39.75% to -$3.9 billion in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$3.9 billion in Q1 2026, -$2.8 billion in Q4 2025, and -$3.0 billion in Q3 2025.